Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Healthcare
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the... see more

NDAQ:LEXX - Post Discussion

Lexaria Bioscience Corp > I have demanded to do a 2 for 1 dividend
View:
Post by SkyLight8 on Nov 22, 2021 11:37pm

I have demanded to do a 2 for 1 dividend

11.4 milllion shares is a still small float  considering we have 4 divisons that can provide major value into 2022
Comment by lscfa on Nov 23, 2021 12:58am
Share count will double soon enough when co. does additional equity raises to pay for all these damn studies.  
Comment by SkyLight8 on Nov 23, 2021 8:28am
LOL you dont know what your talking about revenues are growing and current cash postion 2023 2nd quarter add 11 million worth warrant when we get to 15 should get at least 2 inds to phase 1 each ind apprved is worth 80 million  at 160 million cap sure feed more scum on wallstreet
Lexaria Bioscience Corp